Trecator

(Ethionamide)

Phase 2Small molecule

WWyeth-Lederle Vaccines

Trecator is one of 37 small molecule programs targeting Pulmonary Tuberculosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Pulmonary TuberculosisActive, not recruiting

NACRecruiting

Pulmonary TuberculosisPreclinical

Active, not recruiting

NACPhase 2

Recruiting

Competition

Competitive Landscape

36 competitors in Pulmonary Tuberculosis

#DrugCompanyPhaseTrials

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

9 2

Priftin

Sanofi

Approved

1 3

Myambutol

VVA Greater Los Angeles Healthcare System

Approved

6 4

Calciferol

Avelox

6 6

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—7

Kenalog

BBausch Health Americas, Inc.

Rayos

Decadron

AAspen Global Incorporated

Approved

—10

Amoxil

GGlobal Antibiotics Research and Development Partnership

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

NAC

NCT05807399

Clinical

Trials by Indication[1]

Phase 21 trial

A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098

Completed·TTASK Applied Science·Phase 2·NCT05473195·105 enrolled

Tuberculosis1 trial

An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis

Completed·UUniversity of Cape Town·Phase 2/3·NCT02454205·154 enrolled

Pulmonary Tuberculosis1 trial

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000796·525 enrolled

NAC1 trial

PanACEA - STEP2C -01

Recruiting·MMichael Hoelscher·Phase 2·NCT05807399·390 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

TRECATOR

NDA NDA013026

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Ethionamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ethionamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ethionamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA013026). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Wyeth-Lederle Vaccines company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWyeth-Lederle Vaccines

Trecator

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Phase 21 trial

Tuberculosis1 trial

Pulmonary Tuberculosis1 trial

NAC1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News